BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Gearing Up For August Approval
BioMarin needs to persuade payers that a $2-3m price tag for gene therapy is good value compared to conventional therapy • Source: BioMarin 
